Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which...
41 insider purchases on record · latest filing 2026-08-19.
Insiders have also filed 352 sale transactions at KROS.